• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

药物制剂中从衰变的钍-227去除镭-223的分离技术开发。材料筛选与方法开发。

Development of separation technology for the removal of radium-223 from decayed thorium-227 in drug formulations. Material screening and method development.

作者信息

Frenvik Janne Olsen, Kristensen Solveig, Ryan Olav B

机构信息

a Bayer AS , Oslo , Norway ;

b School of Pharmacy, University of Oslo , Oslo , Norway.

出版信息

Drug Dev Ind Pharm. 2016 Aug;42(8):1215-24. doi: 10.3109/03639045.2015.1118494. Epub 2015 Dec 7.

DOI:10.3109/03639045.2015.1118494
PMID:26569601
Abstract

Targeted thorium conjugates are currently being investigated as a new class of alpha-radiopharmaceuticals. The natural decay of thorium-227 ((227)Th) results in the ingrowth of radium-223 ((223)Ra). Consideration must, therefore, be given to define acceptable limits of (223)Ra in the drug product at the time of dose administration. By effective sequestration of (223)Ra, we aim to improve the radiochemical purity and extend the effective user window of drug products containing (227)Th. (223)Ra is the first progeny of (227)Th and the only one with a long half-life (days). We have, therefore, focused on the removal of this specific species since the progenies of (223)Ra will have a very limited lifetime in the formulation once (223)Ra is removed. In this study, we investigated a multitude of materials for their ability to reduce the (223)Ra level by: (1) passive diffusion or (2) by cartridge filtration on gravity columns. In addition, we probe the compatibility of these materials in the presence of antibody trastuzumab to assess the level of protein binding and estimate the quenching of radiolysis by binding of radionuclides. A screening matrix of organic and inorganic materials was established, i.e. strontium and calcium alginate gel beads, distearoyl phosphatidylglycerol (DSPG) liposomes, ceramic hydroxyapatite, Zeolite UOP type 4A and cation exchange resins AG50W-X8 and SOURCE 30S. First, passive diffusional uptake of (223)Ra by suspended materials present in the formulation was measured as a decrease in sample radioactivity after separation. Second, selected materials were packed on gravity columns in order to evaluate the efficiency of column separation versus diffusional adsorption. The retention of (223)Ra and (227)Th were characterized by measuring the radioactivity in the eluate and on the columns. Finally, the compatibility between trastuzumab, as a selected model antibody, and suspensions of the binding materials was analyzed during storage of the drug product in the presence of adsorbent. The formation of H2O2 was evaluated to measure the influence of radionuclide binding material on radiolysis in the formulation. All the materials bound (223)Ra by passive diffusional uptake ranging from 31% to 95% with DSPG liposomes demonstrating superiority at 95% efficiency. All materials suitable for assessment by gravity column filtration bound (223)Ra almost quantitatively (∼100%) and with minimal variation (relative standard deviation  <1%). The uptake was significantly higher compared to passive diffusional uptake. Alginate gel beads, ceramic hydroxyapatite and SOURCE 30S reduced the antibody concentration in solution to 40-50% while the Zeolite UOP type 4A, AG50W-X8 resin and DSPG liposomes showed ≤10% reduction of antibody concentration. Ceramic hydroxyapatite significantly reduced H2O2 formed by radionuclide initiated radiolysis.

摘要

靶向钍偶联物目前正作为一类新型的α放射性药物进行研究。钍-227((227)Th)的自然衰变会导致镭-223((223)Ra)的生长。因此,在给药时必须考虑确定药品中(223)Ra的可接受限度。通过有效隔离(223)Ra,我们旨在提高含(227)Th药品的放射化学纯度并延长其有效使用期。(223)Ra是(227)Th的第一代子体,也是唯一具有较长半衰期(数天)的子体。因此,由于一旦去除(223)Ra,其后代在制剂中的寿命将非常有限,我们将重点放在去除这一特定物种上。在本研究中,我们研究了多种材料通过以下方式降低(223)Ra水平的能力:(1) 被动扩散或 (2) 通过重力柱上的柱过滤。此外,我们探究了这些材料在存在抗体曲妥珠单抗的情况下的兼容性,以评估蛋白质结合水平并估计放射性核素结合对辐射分解的淬灭作用。建立了有机和无机材料的筛选矩阵,即海藻酸锶和钙凝胶珠、二硬脂酰磷脂酰甘油(DSPG)脂质体、陶瓷羟基磷灰石、UOP 4A型沸石以及阳离子交换树脂AG50W-X8和SOURCE 30S。首先,测量制剂中悬浮材料对(223)Ra的被动扩散摄取,方法是分离后测量样品放射性的降低。其次,将选定的材料填充到重力柱上,以评估柱分离相对于扩散吸附的效率。通过测量洗脱液和柱上的放射性来表征(223)Ra和(227)Th的保留情况。最后,在药品与吸附剂共存的储存过程中,分析作为选定模型抗体的曲妥珠单抗与结合材料悬浮液之间的兼容性。评估过氧化氢的形成以测量放射性核素结合材料对制剂中辐射分解的影响。所有材料通过被动扩散摄取结合(223)Ra的效率在31%至95%之间,DSPG脂质体表现最优,效率为95%。所有适合通过重力柱过滤评估的材料几乎定量地(约100%)结合(223)Ra,且变化极小(相对标准偏差<1%)。与被动扩散摄取相比,摄取量显著更高。海藻酸凝胶珠、陶瓷羟基磷灰石和SOURCE 30S将溶液中的抗体浓度降低至40 - 50%,而UOP 4A型沸石、AG50W-X8树脂和DSPG脂质体使抗体浓度降低≤10%。陶瓷羟基磷灰石显著降低了由放射性核素引发的辐射分解所形成的过氧化氢。

相似文献

1
Development of separation technology for the removal of radium-223 from decayed thorium-227 in drug formulations. Material screening and method development.药物制剂中从衰变的钍-227去除镭-223的分离技术开发。材料筛选与方法开发。
Drug Dev Ind Pharm. 2016 Aug;42(8):1215-24. doi: 10.3109/03639045.2015.1118494. Epub 2015 Dec 7.
2
Development of separation technology for the removal of radium-223 from targeted thorium conjugate formulations. Part I: purification of decayed thorium-227 on cation exchange columns.从靶向钍共轭制剂中去除镭-223的分离技术开发。第一部分:阳离子交换柱上衰变钍-227的纯化。
Drug Dev Ind Pharm. 2017 Feb;43(2):225-233. doi: 10.1080/03639045.2016.1234484. Epub 2016 Sep 26.
3
Development of separation technology for the removal of radium-223 from targeted thorium conjugate formulations. Part II: purification of targeted thorium conjugates on cation exchange columns.从靶向钍偶联物制剂中去除镭-223的分离技术的开发。第二部分:阳离子交换柱上靶向钍偶联物的纯化。
Drug Dev Ind Pharm. 2017 Sep;43(9):1440-1449. doi: 10.1080/03639045.2017.1318906. Epub 2017 Apr 27.
4
Preparation of Pb-labeled monoclonal antibody using a novel Ra-based generator solution.使用新型基于镭的发生器溶液制备铅标记单克隆抗体。
Nucl Med Biol. 2017 Aug;51:1-9. doi: 10.1016/j.nucmedbio.2017.04.005. Epub 2017 Apr 26.
5
Feasibility of Thorium-227/Radium-223 Gamma-Camera Imaging During Radionuclide Therapy.钍 227/镭 223γ-相机成像在放射性核素治疗中的可行性。
Cancer Biother Radiopharm. 2020 Sep;35(7):540-548. doi: 10.1089/cbr.2019.3516. Epub 2020 Jun 2.
6
Optimization of Cation Exchange for the Separation of Actinium-225 from Radioactive Thorium, Radium-223 and Other Metals.优化阳离子交换以分离锕-225 放射性钍、镭-223 和其他金属。
Molecules. 2019 May 18;24(10):1921. doi: 10.3390/molecules24101921.
7
Development of liposomes entrapped in alginate beads for the treatment of colorectal cancer.用于治疗结直肠癌的包裹在藻酸盐珠中的脂质体的研制。
Int J Biol Macromol. 2016 Jan;82:687-95. doi: 10.1016/j.ijbiomac.2015.09.052. Epub 2015 Oct 14.
8
Radiochemical Quality Control Methods for Radium-223 and Thorium-227 Radiotherapies.镭-223 和钍-227 放射性疗法的放射化学质量控制方法。
Cancer Biother Radiopharm. 2023 Feb;38(1):15-25. doi: 10.1089/cbr.2022.0023. Epub 2022 Sep 23.
9
Radioactivity and associated radiation hazards in ceramic raw materials and end products.陶瓷原材料及最终产品中的放射性及相关辐射危害。
Radiat Prot Dosimetry. 2013 Dec;157(3):383-91. doi: 10.1093/rpd/nct149. Epub 2013 Jun 13.
10
Measurement of the 226Th and 222Ra half-lives.
Appl Radiat Isot. 2012 Sep;70(9):1913-8. doi: 10.1016/j.apradiso.2012.02.117. Epub 2012 Mar 7.